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Combined radiotherapy and hyperthermia offer great potential for
the successful treatment of radio-resistant tumours through thermo-
radiosensitization. Tumour response heterogeneity, due to intrinsic, or
micro-environmentally induced factors, may greatly influence treatment out-
come, but is difficult to account for using traditional treatment planning
approaches. Systems oncology simulation, using mathematical models
designed to predict tumour growth and treatment response, provides a
powerful tool for analysis and optimization of combined treatments. We pre-
sent a framework that simulates such combination treatments on a cellular
level. This multiscale hybrid cellular automaton simulates large cell
populations (up to 107 cells) in vitro, while allowing individual cell-cycle
progression, and treatment response by modelling radiation-induced mitotic
cell death, and immediate cell kill in response to heating. Based on a cali-
bration using a number of experimental growth, cell cycle and survival
datasets for HCT116 cells, model predictions agreed well (R2. 0.95) with
experimental data within the range of (thermal and radiation) doses tested
(0–40 CEM43, 0–5 Gy). The proposed framework offers flexibility for mod-
elling multimodality treatment combinations in different scenarios. It may
therefore provide an important step towards the modelling of personalized
therapies using a virtual patient tumour.
1. Introduction
Cancer is a complex disease, with a variety of approaches available for its treat-
ment. Treatment modalities are often combined to maximize response and to
overcome the limitations of individual modalities when used alone. One such
example is the combination of radiotherapy (RT) with hyperthermia (HT), i.e.
non-ablative sustained heating (41–508C applied for times up to  1 h) for
the treatment of radiation-resistant tumours, or tumour sub-regions. Heat has
a radio-sensitizing effect on cell lines of both normal and malignant origin
[1–3]. Heating applied locally to a tumour may therefore enhance treatment
outcome without increasing the risk of normal tissue complications. The intra-
cellular mechanisms involved in thermo-radiosensitization are still subject to
investigation. However, it is believed that a major cause of this synergism is
an inhibition of DNA repair mechanisms by heat, leaving themmore vulnerable
to radiation-induced DNA strand breaks [4–6]. Radiation induced cell death is
a highly regulated cellular process. Depending on factors such as the severity of
the damage, cell-cycle stage and cell type, a response cascade, which will not
only drive pro-survival repair pathways, but also trigger programmed cell
death, is activated [4,7–9]. Once DNA damage is recognized, cell-cycle
& 2018 The Author(s). Published by the Royal Society under the terms of the Creative Commons Attribution
License http://creativecommons.org/licenses/by/4.0/, which permits unrestricted use, provided the original
author and source are credited.
 on January 17, 2018http://rsif.royalsocietypublishing.org/Downloaded from 
checkpoint inhibition will prevent cycle progression to allow
time for damage repair. Depending on the cell’s current stage
in its cycle, the allowed duration of cell-cycle arrest, as well as
the availability of different DNA repair pathways, varies,
leading to differences in repair capacity between cell-cycle
stages. However, prolonged activation of repair and cell-
cycle arrest drive prodeath pathways, resulting, if repair is
unsuccessful, in cell kill via apoptosis, necroptosis or autop-
hagy depending on both the cell type and the severity of the
damage [4,7]. If the cell-cycle checkpoint functionality is
compromised, unrepaired DNA damage will be inherited by
daughter cells and may result in the formation of highly
aneuploid cells with abnormal phenotype (giant cells) that
eventually die or are unable to reproduce (mitotic catastrophe).
This mitotic cell death is therefore not instantaneous but may
take several cycles to manifest itself. Cellular senescence,
i.e. irreversible cell-cycle arrest, is another potential result of
severe DNA damage. Senescent cells do not proliferate but
remain metabolically active [4,7]. In order to predict the
dynamic treatment response of a tumour, or of a cell popu-
lation, in general, it is therefore important to consider these
various reaction pathways.
Systems oncology simulations [10–14] provide a powerful
tool for analysis and optimization of treatment combinations,
and make it possible to take inhomogeneities in the delivered
heating profiles into account. In general, two types of simu-
lation approaches, continuum and discrete models, are
considered. Continuum-based approaches describe macro-
scopic cell densities and substrate concentrations according
to reaction–diffusion processes using sets of partial and
ordinary differential equations (PDEs and ODEs) [11]. Dis-
crete approaches, such as cellular automaton models, track
individual cells or even sub-cellular elements [11]. These
are usually represented as lattice points on a simulation
grid with all actions being governed by a set of predefined
rules. Hybrid models combine both approaches and model
biophysical processes on scales ranging from cellular to
macroscopic using a mix of predefined transition rules and
PDE-driven processes, such as the diffusion of nutrients or
messaging molecules. Recent publications in the field of com-
putational modelling of cancer therapies span a broad range,
from modelling cell response in vitro [15–17] to modelling
angiogenesis and tumour vasculature effects [18,19], the pre-
diction of treatment outcome for patients [20,21] treated with
a variety of approaches, and even to describing the evolution
of different cancer types [22].
Although several studies have looked into modelling
radio- and chemo-therapy response [10,18,23], studies report-
ing the effects of combination treatments of radiation and
heat are few. Several groups have investigated the mathemat-
ical modelling of therapy outcome in terms of cell surviving
fractions [3,24–26].
We here present an implementation of a hybrid cellular
automaton model which simulates the response of cells to
heat, RT or combinations of the two, on several different
spatio-temporal scales. Temporally, the simulation covers
modelling a cell’s cycle progression (minutes), cellular div-
ision and treatment response (hours), up to the modelling
of the growth of the whole population over the course of a
treatment (days). Spatially, the simulation ranges from simu-
lating individual cells (mm) to dealing with macroscopic cell
culture dishes (  107 cells, cm scale). The multiscale nature of
the model therefore requires analysis of the effects of single
and combination treatments on individual cells, and on the
cell population as a whole. The aim of this model was the pre-
diction of response to the treatment of a large-cell population
in vitro, i.e. to predict the number and distribution of viable
cells over time, in order to provide an important first step
towards more complex modelling of tumours in vivo. This
requires finding a compromise between the simplest model
that summarizes a cascade of complex biological processes,
and a model that is sufficiently complex to describe the
observed biological behaviour and is based on known key
response pathways.
2. Methods
2.1. Model implementation
The model presented here is a significant development of the
previous model of Powathil et al. [23,27], with new implemen-
tation in Cþþ. This is a cellular automaton model for the
simulation of response to therapy using the recently developed
AlphaR survival model designed specifically for calculating cell
surviving fractions after multimodality treatments [26]. Besides
enabling the introduction of heat as a second treatment modality,
the simulation framework has been extended to include dynamic
modelling of mitotic cell kill after irradiation. Optimization of the
implementation has further allowed an extension of the simu-
lation to large cell populations (of the order of several million
cells). This is required for direct comparison between experimen-
tal and simulated data. We show that our model can predict the
dynamic growth of a treated cell population once key model
parameters have been adjusted using experimentally derived
in vitro data.
2.1.1. Growth modelling
Digital cells are represented as voxels on a two- or three-dimen-
sional lattice depending on the experimental set-up to be
simulated. Thus, the diameter of a cell corresponds to the edge
length of a voxel. The following discussion of in vitro exper-
iments is restricted to the representation of cell monolayers in
culture dishes, which are simulated as flat, two-dimensional
lattices.
In agreement with the known cell-cycle progression of real
cells [28,29], each virtual cell follows the well-known four-stage
cycle through G1, S, G2 and M-phases. Cycle stages are assigned
according to an individual cell-cycle timer that is incremented in
each time frame according to the predefined growth rate of that
cell type. To account for variation in cycle duration for cells
within a population, growth rates are assigned using a normal
distribution, with a mean growth rate corresponding to the exper-
imentally determined rate for the specific cell type, and a standard
deviation of 5% of this value. Upon division, a cell’s neighbour-
hood (i.e. Von Neumann (directly adjacent voxels), or Moore
(directly and diagonally adjacent voxels) neighbourhoods) is
scanned for free spaces up to third-order neighbours. Moore
and Von Neumann neighbourhoods are applied alternately to
give circular growth of the cell colony. From all free spaces, an
empty voxel is randomly selected for the new position of the
daughter cell, with positions closest to the parental cell being occu-
pied first. For simplicity, during these relatively short-term studies
(up to two weeks), all cells are assumed to have an infinite life
span and unlimited division potential in the absence of external
damage, resulting in exponential population growth. However,
experimental cellular growth curves in vitro (i.e. number of cells
present as a function of time) are characterized by an initial lag
period during which the cells attach and adapt to their new
environment, followed by exponential growth. A lag phase of
2 h was therefore introduced into our simulations. During this
rsif.royalsocietypublishing.org
J.R.Soc.Interface
15:20170681
2
 on January 17, 2018http://rsif.royalsocietypublishing.org/Downloaded from 
phase, digital cells do not progress through their cycle, but may
die if treatment is delivered during this time.
In a culture dish, a cell population eventually reaches conflu-
ence, and proliferation decreases due to a lack of space and
increased competition for nutrients. This results in a plateau in
the growth curve. A fifth stage, G0, is introduced to account for
this behaviour. G0 represents a reversible resting stage (quies-
cence). It is entered if a cell is no longer able to divide due to a
lack of free space nearby. Quiescent cells arrest their cycle until
neighbouring spaces are vacated, or the cell is killed. For a simu-
lated culture dish of a predefined geometry, the number of cells
at which the plateau is reached depends only on the number of
voxels present, thus making it necessary to adapt the voxel
size to model the shape of a simulated plateauing growth
curve correctly. This will be described in detail in §3.1.1.
Figure 1 shows a flow chart which describes the simulation of
normal cell growth.
2.2. Treatment response modelling
2.2.1. Radiotherapy
Radiation is simulated as being delivered homogeneously to all
cells in each fraction. Cell survival after radiation, SRT, is esti-
mated as a function of dose d using the AlphaR model [26],
extended by a cycle stage-dependent weighting factor g to
account for differences in radiation sensitivity at each stage [23].
 log (SRT) ¼
g((a0  aR)dþ bd2) d  DT ¼ aR2b
g a0d a
2
R
4b
 
d . DT:
8<
: ð2:1Þ
The AlphaR model uses three cell line and treatment-dependent
parameters: a0, aR and b. These describe a combination of cellu-
lar damage (a0), damage repair (aR) and reduction of the repair
capacity with increasing dose (b). DT represents a threshold dose
above which no damage repair is possible. Whereas for doses
lower than DT, survival is described by a linear-quadratic (LQ)
exponential function, the cell survival curve is described by a
single exponential for doses exceeding this threshold.
The advantage of the AlphaR model over others, such as the
LQ model [30], is its applicability to multimodality therapies. In
particular, HT cell survival curves, which are characterized by a
strong shoulder followed by an exponentially linear decay, are
well described by this model. More information on the cell
survival model used is provided in [26].
As for most cell survival models, the AlphaR model relates to
survival as measured by clonogenic assays [31]. This assay is
conducted several days post treatment, and therefore does not
give information about the dynamics of cell damage and
repair. In the range of doses used therapeutically, radiation-
induced cell killing is not instantaneous, but occurs as a conse-
quence of the cell’s inability to undergo division successfully
[4,7,8]. This means that irradiated cells may continue to prolifer-
ate, become senescent or form giant cells with multiple nuclei
(mitotic catastrophe) before undergoing apoptosis. It is impor-
tant to take this into account as growth restrictions due to
space or nutrient limitations, as well as processes such as re-
oxygenation (where three-dimensional growth is considered)
will be affected by these dying cells.
Previous simulations have accounted for this observation by
artificially increasing the surviving fraction predicted by the cell
survival model (e.g. [23,27,32]). However, such an implemen-
tation does not reflect actual cellular behaviour, and has not
been verified experimentally. In our model, we approximate
the dynamics of radiation-induced cell killing using a series of
random events as outlined in the decision tree shown in
figure 2. Each cell that receives radiation in the simulation, will
die with a probability 1-SRT (SRT being the calculated surviving
fraction). However, radiation-induced cell kill is not simulated
as being instantaneous, rather, the dying cells are assigned a ran-
domly selected delay period between irradiation and time of
death. These delays to cell death are sampled from an exponen-
tial distribution with exponent kdelay which has to be determined
from experimental data (see §2.4). During the delay period, cells
keep proliferating, but any daughter cells created will die at the
same time as their parent. Besides normal proliferation, dying
cells can also enter mitotic catastrophe at the end of M-phase,
with a probability pmitoticCat. Cells undergoing mitotic cell
death either form giant cells with their size increasing at each
attempted division, or they become senescent with probability
psenescence, i.e. they cease to proliferate but are still viable. This
allows for a small population of surviving, but non-proliferating
cells. It should be stressed that, although motivated by exper-
imental observations, this simulation provides a mathematical
construct that provided the best balance between a biologically
motivated description and simplifying approximations to build
a time efficient simulation. The actual underlying biological pro-
cesses may, however, be far more complex, and it was the aim of
this study to provide a deliberately simple implementation with
few model parameters to vary.
2.2.2. Cellular heat response
For the experimental procedure described below, heat treatments
are simulated as temporally homogeneous exposures, such as are
performed in a thermal cycler. The biological effect of these treat-
ments depends on treatment temperature and duration. To
compare different heating profiles, and to quantify the effects
of the applied heat distribution at a cellular level, the ‘thermal
dose’ concept [33] is used. Thermal dose is defined in terms of
the equivalent time at a constant temperature of 438C (measured
in units described as CEM43) required to yield the same number
of surviving cells as from a different arbitrary combination of
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Figure 1. Flow chart showing the implementation of normal cell growth.
According to its cycle timer a virtual cell follows a four-stage cycle consisting
of G1, S, G2 and M-phases. Once the cycle timer exceeds the threshold time
tstage, the cell is assigned to a new cycle stage. Once the cycle timer reaches
the doubling time tdouble, the cell will either divide into two cells in stage G1
or enter the reversible quiescent stage G0, if no free neighbouring spaces are
available. (Online version in colour.)
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heating time and temperature. It is calculated using a two-case
model distinguishing between heating above and below a
threshold temperature of 438C to account for the activation of
different biological processes at these temperature levels: for a
number of heating steps i, heating times ti at a temperature Ti
are expressed in terms of equivalent heating time at 438C, t43.
t43 ¼
X
i
ti  R43Ti with R ¼ 0:25 TX  43
C
0:5 TX . 43C:

ð2:2Þ
For the calculation of the total thermal dose from a treatment,
time steps ti with temperatures exceeding 408C are taken into
account. In a similar manner to the implementation of the
cellular response to radiation, the AlphaR model surviving
fraction is used to evaluate the fate of an HT as a function of
thermal dose, SHT(t43). For this, the dose parameter d in equation
(2.1) is replaced by the total thermal dose, t43, according to
equation (2.2).
 log(SHT(t43))
¼
g((a0,HTaR,HT)t43þbHTt243) t43DT¼ aR,HT2bHT
g a0,HTt43 a
2
R,HT
4bHT
 
t43.DT:
8<
:
ð2:3Þ
The model parameters a0, aR and b are replaced by the cell line-
specific parameters determined from HT cell survival curves,
a0,HT, aR,HT and bHT. In the simulation, HT-induced cell killing
is modelled to occur instantaneously, and no further cell-cycle
delay is applied.
2.2.3. Combination treatments
Similar to the implementation of heat alone, and radiation alone
induced cell killing, cell surviving fractions resulting from com-
bined RT and HT treatments, SRTHT(d, t43), with thermal dose
t43, and radiation dose d, are first calculated. As reference data
were only available for the LQ branch of the AlphaR model in
this case, surviving fractions are calculated as follows:
SRTHT(d, t43) ¼ SHT(t43)  e(aRTHT(t43)dþbRTHT(t43)d2),
aRTHT(t43) ¼ aRT þ a  t43
and bRTHT ¼ bRT:
9>=
>; ð2:4Þ
Here, SHT(t43) is the surviving fraction due solely to the heat treat-
ment. Heat-induced radio-sensitization is described by a thermal
dose-dependent parameter aRTHT that increases linearly with ther-
mal dose according to a cell line-dependent slope a, whereas bRTHT
is assumed to be constant. aRT (aRT¼ a0,RT2 aR,RT), and bRT refer
to radiation only treatments. These thermal dose dependencies
were analysed in detail in [26] for the cell line used here, and in
[34–36] using a very similar parametrization for different cell lines.
In simulating the dynamic cell kill in response to combi-
nation treatments, cells are immediately ‘killed’ according to
the surviving fractions derived from the heat contribution of
the treatment, i.e. a fraction of 12 SHT cells is removed from
the grid. Of the remaining cells, 12 SRTHT(d, t43)/SHT(t43)
(equation (2.4)) are assigned a time delay before cell death
sampled from an exponential distribution as described for the
simulation of RT alone cell kill (see flow chart in figure 2).
2.3. Experimental procedure for calibration and
validation experiments
A number of experiments were performed to calibrate the simu-
lation framework used to model the response of the colorectal
carcinoma cell line HCT116. These included growth curves,
cell-cycle analysis and clonogenic cell survival assays (published
in [26]).
For all experiments, HCT116 cell monolayers were grown at
378C in McCoy’s 5A medium (Gibco, Paisley, UK) supplemented
with 10% fetal bovine serum (PAN Biotech, UK) and 1% anti-
biotics (50 Uml21 each of penicillin, streptomycin B and
amphotericin B (Sigma Aldrich, Poole, UK)) in a humidified
atmosphere containing 5% CO2. Cells were passaged twice
HT only
N > SHT
RT only
N > SRT
death delayed
delay timer assigned
instantaneous
death
death (delay timer = 0)
giant cell:
occupy another
voxel
senescence:
exit cell cycle
proliferating stop dividing
M-phase:
1–pmitoticCat pmitoticCat
M-Phase: 
psenescence 1–psenescence
RTHT
N > SHTSHT > N > SRTHT
mixed response
Figure 2. Decision tree used to simulate treatment response to radiation, heat and combination treatments for each individual cell. According to a random number
N[0, 1] drawn for each cell, a decision is made whether the cell lives (N  S) or dies. The respective surviving fractions after heat alone, SHT, radiation alone, SRT, or
combination treatment, SRTHT, were calculated using equations (2.1), (2.3) and (2.4). Whereas heated cells (HT) are assumed to die instantaneously, irradiated cells
(RT) are assigned a time delay before death which is sampled from an exponential distribution. Until this time point is reached, dying cells either keep dividing (with
probability 12 pmitoticCat), or undergo mitotic catastrophe and become either a giant cell (with probability 12 psenescence) or a senescent cell (with probability
psenescence). For combination treatments (RTHT), cells die instantaneously if N . SHT, or follow radiation-induced delayed cell death if SHT. N . SRTHT. (Online
version in colour.)
rsif.royalsocietypublishing.org
J.R.Soc.Interface
15:20170681
4
 on January 17, 2018http://rsif.royalsocietypublishing.org/Downloaded from 
weekly using the gentle detaching agent Accutase (Gibco,
Paisley, UK). Regular screening for mycoplasma and bacterial
contamination was undertaken, and cells in exponential growth
phase between passages 10 and 20 were used for experiments.
For treatments, cells were detached, concentrated to give a
suspension of 5  106 cells ml21 and transferred to sterile, thin-
walled PCR tubes (VWR, Lutterworth, UK) in 60ml volumes.
For irradiation, tubes containing cells were embedded in a solid
water sample holder and irradiated using a small animal radiation
research platform (SARRP, X-Strahl, Camberley, UK) at a dose rate
of 63mGy s21. Heating to 468C for 5min was performed in a
Biorad Tetrad2 DNA Engine PCR thermal cycler (Hercules, CA,
USA) using the techniques described in [26,37]. Cells were kept
on ice before, between and after treatments to minimize cellular
activity during waiting periods. For combination treatments,
cells were first irradiated, and then heated within 20min of this
irradiation. It was confirmed experimentally that if heating was
applied within 30min, the delay between irradiation and heating
made no difference to the subsequent clonogenic cell survival [26].
For fractionated treatments, plates seeded with the required
number of cells were irradiated every 24 h using an X-ray cabinet
(X-Strahl, Camberley, UK, dose rate 63mGy s21).
2.3.1. Growth curves
Cell growth curves were acquired by seeding triplicates of treated
cells in 24- or six-well plates depending on the expected number
of surviving cells. Seeding densities ranged from 2  104 cells/
24-well plate to 5.4  105 cells/six-well plate depending on the
treatment given. Cell number was determined at various time
points (24–200 h) after treatment by counting detached cells in
a haemocytometer. A minimum of 100 cells in a minimum of
three 1  1mm2 were counted for each replicate. For each data
point, the average cell count and corresponding standard devi-
ations of three replicates were taken. Growth curves were also
acquired at comparable cell densities in 96-well plates. Cells in
96-well plates were fixed with ice-cold 10% trichloroacetic acid,
and subsequently stained with sulforhodamine B (Sigma
Aldrich, Poole, UK) before being imaged with bright-field
microscopy to study cell morphologies.
2.3.2. Cell-cycle analysis
For cell-cycle analysis, cells were detached, washed in ice-cold
phosphate-buffered saline and fixed in ice-cold 70% ethanol.
Fixed cells were treated with RNase to minimize non-specific
background staining, and stained with the DNA-intercalating
dye propidium iodine (PI, Sigma Aldrich, Poole, UK) for
15min at room temperature in the dark prior to analysis using
flow cytometry in an LSRII analyser (BD, Franklin Lakes, NJ).
DNA content of at least 104 cells was measured in this way
and data were collected using DiVa (BD, Franklin Lakes, NJ).
The resultant histograms were fitted by the Watson pragmatic
model in FlowJow to obtain cell-cycle distribution proportions.
2.3.3. Clonogenic assays
Clonogenic cell survival data have been published in [26] for
HCT116 cells. Table 1 summarizes all parameters used for calcu-
lating clonogenic surviving fractions for possible treatment
scenarios for this cell line. For RT and RTHT treatments, the
LQ arm of the AlphaR model was sufficient to describe the cell
survival data obtained for the radiation doses used here. There-
fore, no individual values for a0, and aR are needed, and the
difference between these parameters, (i.e. a ¼ a0 2 aR), is
given. For HT treatments a0 ¼ aR (see [26] for details).
2.4. Parameter fitting upon model calibration
Where it was not possible to measure model parameters exper-
imentally, these were adjusted to yield the best overall
agreement in terms of coefficients of determination R2 between
simulated and reference data during calibration of the model.
For model validation, no further changes were made to the par-
ameters used. Table 2 gives an overview of all parameters used
in this simulation and the method used for their determination.
3. Results
3.1. Model calibration
3.1.1. Cell-cycle distribution and growth
The simulation framework was first calibrated to model the
growth and treatment response of the colorectal carcinoma
cell line HCT116. Cellular growth curves were used to deter-
mine cell doubling time and voxel size, while flow cytometry
was used to obtain information about the cell-cycle distribution.
Figure 3 shows the resulting histogram of the cellular
DNA content separated into G1, S and G2/M phase, as well
as a table of the percentage of cells in, and duration of,
each cycle phase. As flow cytometry cannot distinguish
between cells in M- or G2-phase (because they have the
same DNA content), it was assumed that the 25% of cells
in both phases is split into 20% G22 , and 5% M-phase.
Figure 4 shows the correspondinggrowth curve for 2.3  104
cells seeded in a 24-well plate (15.6mm well diameter) along
with the calibrated simulation. Data points and error bars corre-
spond to mean and standard deviation values from three
replicates of a single experiment. An average doubling time of
19.5+1 h was measured for HCT116 cells. A good simulation
of the growth curve plateau was obtained for voxel sizes of
9.6  9.6mm2 and 12 12mm2 if cells in 24-well or six-well
Table 1. AlphaR-model parameters (with their time and temperature dependence) used to simulate the treatment response of HCT116 cells.
a5 a0 2 aR a0 b
RT 0.5 Gy21 — 0.042 Gy22
HT 0 0:05  e0:67C1(T43C) min1 a201:95 min2
RTHT 0:5 Gy1 þ 0:015  t43 Gy1 min1 — 0.042 Gy22
Table 2. Summary of all parameters used in this simulation framework
together with the method used for parameter estimation.
parameter calibration method
a, a0, aR,b clonogenic assay
growth rate growth curve
number of cells in plateau phase growth curve
cell-cycle distribution ﬂow cytometry
initial number of cells N0 haemocytometer count
pmitoticCat, psenescence, kdelay ﬁt of R
2
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plateswere simulated.Differences in voxel size determined from
the plateau cell density in the two well types may be due to
changes in nutrient medium volume-to-surface-ratios, as well
as to variations in frequency of medium change for different
samples.
3.1.2. Treatment response
The simulation is first adapted to match the growth of
HCT116 cells irradiated with 5 Gy. This was achieved by
adjusting the exponent kdelay, and the probability pmitoticCat
that characterize the distribution of delay times to cell
death, and the probability of undergoing mitotic catastrophe
after radiation treatments. Figure 5a,b shows the resulting
growth of 2.6  105 irradiated cells seeded in a six-well
plate with the corresponding simulation assuming (a) instan-
taneous cell kill or (b) controlled delayed cell kill via mitotic
catastrophe using kdelay ¼ 0.009 h21, and pmitoticCat ¼ 0.2.
Neither psenescence nor g significantly changed the simulation
result for these conditions. The probability of cellular senes-
cence, psenescence, was fixed at a value of 5% since we have
assumed a small contribution from senescent cells. The sensi-
tivity between different cycle stages was assumed to be a
constant ratio of 1.5, meaning that surviving fractions Sphase
differ by powers of 1.5 relative to each other: SS ¼ 1.5 .
SG1 ¼ 1.52 . SG2 ¼ 1.53 . SM. This corresponds to factors, g,
ranging from 0.85 (least sensitive, S-phase) to 1.39 (most sen-
sitive, M-phase).
It is clear that a simulation which assumes instantaneous
cell death would greatly underestimate the total number of
cells, whereas in vitro and in silico experiments are in very
good agreement within the boundaries of the 95% confidence
intervals of the calculated surviving fraction (S5Gy ¼
0.04(0.03,0.05)) when delayed cell kill is assumed. Photo-
graphs of fixed, irradiated and untreated cells at three
different growth stages (initially seeded, subconfluent (96 h)
and confluent wells (144 h)) are shown in figure 5c. In the
irradiated samples, giant cells are clearly visible at the sub-
confluent, and confluent stages.
3.2. Model validation and application
HCT116 growth curves for heated (5min at 468C), irradia-
ted (2 Gy, 5  2 Gy, 5  3 Gy), and combination treated cells
(2 Gy irradiation, and heating for 5min at 468C) are simulated
and compared to the corresponding experimental growth
phase
120
90
60
co
u
n
t
30
0
0 50 K 100 K
nuclear DNA content (channel number)
150 K 200 K 250 K
% total
population duration (% total cycle)
G1 41 32
S 34 34
G2 20a 26
M 5a 8
(b)(a)
aDNA content of G2- and M-phase cells is measured
simultaneously in one peak. We split this proportion into
20% G2 and 5% M-phase.
Figure 3. (a) Histogram of the cellular DNA content obtained by flow cytometry. From a fit of the experimental data using the Watson pragmatic model, the
proportions of singlets corresponding to cells in G1-phase (first peak, purple), cells in the process of reproducing their DNA in S-phase (middle part, yellow), and
doublets corresponding to cells in G2- or M-phase are determined (second peak, green). The experimental data (black) and the model fit ( pink) are shown.
(b) Table of cell-cycle distribution, and cycle stage duration as obtained by flow cytometry analysis of untreated HCT116 cells. (Online version in colour.)
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Figure 4. Simulated and experimentally determined growth curves for
untreated HCT116 cells in 24-well plates; 2.3  104 cells with a doubling
time of 19.5 h on a 15.6 mm diameter circular two-dimensional grid (corre-
sponding to a diameter of 1625 voxels) were simulated using the cell-cycle
distribution information given in figure 3. The experimental data points (black
circles, means and standard deviations), as well as the simulated total cell
numbers and simulated contributions from the different cell-cycle stages
(solid lines) are shown.
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curves (figure 6). The calculated surviving fractions are
shown with 95% confidence intervals: S2Gy ¼ 0.31 (0.25,
0.37), S3Gy ¼ 0.15 (0.10, 0.20), S5 min ,46C ¼ 0:26 (0:07,0:44),
S2Gyþ5 min ,46C ¼ 0:03 (0:01,0:05). For all treatment scenarios,
simulation and experimental data are in good agreement.
Although there seems to be a small offset between simulated
and measured growth curves for cells treated with 2 Gy in a
single fraction, this may be explained by a small deviation of
the experimental surviving fraction from the average surviv-
ing fraction calculated by the AlphaR model. However, the
experimental result lies well within the 95% confidence
bounds of the predicted growth curves. In particular, for frac-
tionated treatments, the overall shape of the growth response
curve is well described for both 2 and 3Gy fractions. Having
shown that the simulation framework accurately predicts
different homogeneous irradiation and heat treatments, it
can now be used, for example, to predict the growth response
to different fractionation combinations of radiation and heat.
Since the simulation uses a stochastic succession of events,
the average and standard deviations of 500 runs are taken
for each simulated treatment course. Figure 7 shows the influ-
ence of choosing a different time point for heat application
within the overall treatment schedule involving 30 fractions
of 2 Gy radiation in combination with a single combined treat-
ment (thermal dose of 40 CEM43). Depending on the time of
adding the heat fraction, the overall treatment success in terms
of time until tumour regrowth may be changed slightly due to
the alterations in the proportions of quiescent and proliferat-
ing cells. Based on this observation, this simulation
framework may help to identify the best treatment order for
RTHT therapies for different proportions of proliferating
and quiescent cells at treatment onset.
We also demonstrate that using instantaneous rather than
delayed cell killing in response to RT may change the overall
treatment outcome prediction of fractionated RT treatments
alone (figure 7b) due to different numbers of regrowing
cells in the two simulations. If instantaneous cell kill is con-
sidered, more space is available to allow cell division
compared with the delayed cell kill simulation, where more
cells remain quiescent for a longer period of time.
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Figure 5. Calibrated simulation of a growth curve of 2.6  105 irradiated (5 Gy) HCT116 cells seeded in six-well plates with a diameter of 34.8 mm (corresponding
to a grid diameter of 2900 voxels). The experimental data points (black circles) are shown, as well as the simulated total cell numbers (solid lines) together with
simulation of the 95% confidence bounds of the surviving fractions used (dashed lines, S5Gy ¼ 0.03 (0.02, 0.04)). (a) Simulation assuming instantaneous cell kill
greatly underestimated the total number of cells. (b) Simulation assuming controlled delayed cell kill via mitotic catastrophe was successfully calibrated to match the
experimental data. (c) Photographs of fixed irradiated, and untreated cells at three different growth stages (initially seeded, sub-confluent (96 h) and confluent wells
(144 h)). The pink stain corresponds to cellular protein stained by sulforhodamine B. A change in morphology from normal phenotype to a mixture of normal and
aneuploid cells is seen for irradiated cells.
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4. Discussion
The cellular automaton model presented provides flexibility
for application to the study of a number of different situ-
ations, both in vivo and in vitro. We have successfully
calibrated the model for single and multimodality therapies
of heat and ionizing radiation and could accurately predict
treatment response for one particular cell line. This was
achieved by introducing a delay before cell death, rather
than solely instantaneous death, to describe the cellular
response to irradiation. This is an important difference
between our, and previous [27], implementations.
Cellular growth curves offer the possibility of testing the
simulation in terms of the dynamic development of a treated
population over time, rather than providing an absolute sur-
viving fraction only at the fixed time point post treatment
provided by clonogenic assays. Since most cell survival
models, such as the AlphaR or the LQ, are based on clono-
genic cell survival data, they predict the long-term
surviving fraction, but cannot give any information on how
the population develops towards this endpoint. Growth
curves, on the other hand, provide dynamic information,
but it can be difficult to extrapolate from them to the overall
surviving fraction. Therefore, a combination of surviving frac-
tion, as measured by clonogenic assays, and growth curve
data captures a more complete picture. It is, however, diffi-
cult to measure cell growth within the first few hours after
cell seeding due to the lag between cell seeding, their attach-
ment and exponential growth. Although there might well be
differences in the lag time of treated and untreated cells, all
experiments have here been allocated a constant lag period
of 2 h, resulting in slight differences between experiment
and simulation during the initial growth phase. While correct
modelling of the initial growth phase may be difficult due to
this lag time, the exponential and plateau phase of growth
curves are accessible for model calibration. However, the pla-
teau cell density depends strongly on the nutrients provided,
i.e. the frequency of medium renewal and its overall volume.
When fresh medium is continuously provided, cells in a con-
fluent layer may continue to grow. These new cells may attach
on top of other cells. As only a perfect monolayer of virtual
cells of rigorously controlled size and shape is considered in
this simulation, the voxel size used must be carefully adapted
to the properties of the dishes. Although the voxel size, and
therefore the maximum number of cells per well may be of
importance for simulating fully confluent cells in vitro, the
effects may be less important for tumours in vivo.
Figures 5 and 7b show that it is essential to consider the
impact of delayed reproductive cell death, because instan-
taneous cell death greatly underestimates the number of
living cells during the first days after treatment. This may
influence simulation results, e.g. when studying the effects
of tissue reoxygenation and tumour growth response, since
immediate removal of all dying cells would allow faster
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repopulation and enhanced reoxygenation of the tumour
compared to delayed cell kill simulations. For long-term
studies of single treatment fractions, these delayed effects
should be negligible since the surviving population will
eventually provide the majority of proliferating cells. The par-
ameters used to describe the dynamics of delayed cell kill
(kdelay, pmitoticCat and psenescence) have here been customized
to fit the data from HCT116 cells. Although it might be poss-
ible that some, or all, of these parameters are similar for other
cell types, their accurate modelling would require re-cali-
bration of these parameters.
The calculation of surviving fractions strongly depends
on the biological model parameters used, i.e. a0, aR and b,
in the case of the AlphaR model. These parameters are subject
to relatively large uncertainties and individual experiments
often deviate from the predicted average surviving fraction.
This may be a feature of clonogenic assays, which are very
sensitive to experimental error (e.g. from cell counting and
pipetting uncertainties), and strongly depend on the exper-
imental conditions, such as incubation time, cell-cycle
distribution and density, and cell health in general. This
results in relatively large intra- and inter-experimental differ-
ences, leading to the large reported confidence bounds of the
surviving fractions for HT and combination treatments.
All biological results presented were obtained for a com-
mercially available human cancer cell line. As all reference
experiments were performed by us on the same batch of
cells, rather than using previously published data from a
number of sources, our calibration benefits from a consistent
dataset, which is immune to errors arising from differences in
experimental techniques between different laboratories.
Based on the current results, simulations of other cell types
may either be calibrated using the techniques presented
here, or a sensitivity analysis of the parameters used could
be performed to understand the importance of individual
parameters on the overall simulation outcome (see electronic
supplementary material, appendix A). This would allow
study of the effects of heterogeneous cell populations such
as seen in tumours in vivo.
Although the model provides good predictions within the
calibrated dose range, it should be stressed that doses outside
the range of standard therapies, in particular ablative thermal
doses and large single fraction RT treatments, have not yet
been studied, and may be subject to different cellular
response mechanisms which are not captured by this
implementation. Also, a number of other parameters that
influence the overall cell surviving fraction, e.g. the
irradiation dose rate or time interval between HT and RT
treatments, are not yet included. A recent publication by
van Leeuwen et al. [38] touched on this discussion and pro-
posed an exponentially decaying influence of heat-induced
radiosensitization as a function of time between HT and RT
application. However, there is ongoing discussion concerning
the decay rate of heat-induced radiosensitization which is
considered to be cell line dependent, and may be greatly
influenced by physiological factors such as blood flow lead-
ing to different parameter estimations between in vivo and
in vitro applications even for the same tumour type. Van
Leeuwen et al. recommended using a decay rate of the
order of 2 h. Since in our simulation, RT and HT are con-
sidered to be given simultaneously, and consecutive
radiation fractions are given at least 24 h apart from one
another, we believe that our results remain valid, given we
have included no time factor in the framework at this stage.
Further experimental validation would be required if more
complex heating and radiation schedules using shorter time
intervals between treatment fractions, or longer time gaps
between heat and radiation application, are of interest.
One particularly interesting application of the model is,
therefore, the verification of the thermal dose concept for
temperatures exceeding 488C. Owing to the exponential
relation of thermal dose on treatment temperature, even
small deviations from the proposed mathematical descrip-
tions translate into large differences in thermal dose and
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Figure 7. (a) Simulation results of fractionated treatments using 30 fractions of 2 Gy, of which one fraction is given in combination with a thermal dose treatment of
40 CEM43 at different days within the overall treatment period as indicated by the legend (5  106 cells initially). The means of 500 simulation runs are shown.
Inset: expanded view of the population growth 100–200 days post treatment. Although the overall delivered radiation and thermal doses are the same, depending
on the combination of the treatment fractions, the biological response may vary. (b) Fractionated RT treatment of 30 fractions of 2 Gy simulated using delayed (black
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cell survival in this temperature range. With uniform heating
approaches, it is impossible to verify the thermal dose con-
cept for very high temperatures accurately, since thermal
dose uncertainties originating from heating and cooling
gradients are difficult to account for in such cases. The
proposed framework can be applied to the simulation of
different cell distributions in order to calculate an overall
probability for the expected cell survival.
Moreover, while the combination of focused ultrasound
mediated heating [39,40] with RT provides a promising
approach on paper, it is difficult to verify experimentally at
a cellular level. For treatment and experiment planning, as
well as for determining effective dose and exposure prescrip-
tions, it is essential to first quantify the biological effects at a
cellular level. Systems oncology simulations may provide a
very useful tool for analysis of the effects of different,
inhomogeneous (in space and time) heat and radiation distri-
butions, for which the averaged cell surviving fractions for a
subset of carefully selected scenarios can be verified exper-
imentally. The simulation framework presented here was
designed specifically for such applications. It is possible to
simulate the whole experimental procedure of an in vitro
focused ultrasound experiment, as well as to analyse the
expected overall treatment response of the cell population.
5. Conclusion
We have demonstrated a cellular automaton model that is
suitable for accurate modelling of the dynamic response to
separate, or combined, heat and RT treatments. The inclusion
of delayed rather than instantaneous, cell kill after irradiation
may impact on simulations which aim to study the effects of
reoxygenation and tumour progression, and should therefore
be taken into account. We have presented a simple
implementation for enabling such modelling, and verified
our framework against a consistent experimental dataset
thus making this simulation framework a reliable basis for
future applications where the effects and optimized treatment
protocols for combination treatments in vivo are studied.
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